Anatolii V Kubyshkin

Prof. Dr. Anatolii V Kubyshkin

orcid

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2019 in Molecules
Verified
Journal Article
Open access
PDF file
KLKateryna Laikova
Kateryna Laikova
Vol V. OberemokVol V. Oberemok
Vol V. Oberemok
AKAlisa Krasnodubets
Alisa Krasnodubets
Nikita V. Gal'chinskyNikita V. Gal'chinsky
Nikita V. Gal'chinsky
RURefat Zhevdetovich Useinov
Refat Zhevdetovich Useinov
Anatolii V KubyshkinAnatolii V Kubyshkin
Anatolii V Kubyshkin
Skin cancer has always been and remains the leader among all tumors in terms of occurrence. One of the main factors responsible for skin cancer, natural and artificial UV radiation, causes the mutations that transform healthy cells into cancer cells. These mutations inactivate apoptosis, an event required to avoid the malignant transformation of healthy cells. Among these deadliest of cancers, melanoma and its ‘younger sister’, Merkel cell carcinoma, are the most lethal. The heavy toll of skin cancers stems from their rapid progression and the fact that they metastasize easily. Added to this is the difficulty in determining reliable margins when excising tumors and the lack of effective chemotherapy. Possibly the biggest problem posed by skin cancer is reliably detecting the extent to which cancer cells have spread throughout the body. The initial tumor is visible and can be removed, whereas metastases are invisible to the naked eye and much harder to eliminate. In our opinion, antisense oligonucleotides, which can be used in the form of targeted ointments, provide real hope as a treatment that will eliminate cancer cells near the tumor focus both before and after surgery.

29 May 2018 in Molecules
Verified
Journal Article
Open access
PDF file
Vol V. OberemokVol V. Oberemok
Vol V. Oberemok
KLKateryna Laikova
Kateryna Laikova
ARAnna Igorevna Repetskaya
Anna Igorevna Repetskaya
IKIgor M. Kenyo
Igor M. Kenyo
MGMikhail Gorlov
Mikhail Gorlov
Anatolii V KubyshkinAnatolii V Kubyshkin
Anatolii V Kubyshkin
Antisense oligonucleotides (ASO), short single-stranded polymers based on DNA or RNA chemistries and synthesized in vitro, regulate gene expression by binding in a sequence-specific manner to an RNA target. The functional activity and selectivity in the action of ASOs largely depends on the combination of nitrogenous bases in a target sequence. This simple and natural property of nucleic acids provides an attractive route by which scientists can create different ASO-based techniques. Over the last 50 years, planned and realized applications in the field of antisense and nucleic acid nanotechnologies have produced astonishing results and posed new challenges for further developments, exemplifying the essence of the post-genomic era. Today the majority of ASOs are chemically modified and/or incorporated within nanoparticles to enhance their stability and cellular uptake. This review critically analyzes some successful cases using the antisense approach in medicine to address severe diseases, such as Duchenne muscular dystrophy and spinal muscular atrophy, and suggests some prospective directions for future research. We also examine in detail the elaboration of unmodified insect-specific DNA insecticides and RNA preparations in the areas of agriculture and forestry, a relatively new branch of ASO that allows circumvention of the use of non-selective chemical insecticides. When considering the variety of successful ASO modifications with an efficient signal-to-noise ratio of action, coupled with the affordability of in vitro oligonucleotide synthesis and post-synthesis procedures, we predict that the next half-century will produce a fruitful yield of tools created from effective ASO-based end products.

16 June 2016 in Inflammation Research
Verified
Journal Article
Closed access
PDF file
Anatolii V KubyshkinAnatolii V Kubyshkin
Anatolii V Kubyshkin
LAL. L. Aliev
L. L. Aliev
IFI. I. Fomochkina
I. I. Fomochkina
YKYe. P. Kovalenko
Ye. P. Kovalenko
SLS. V. Litvinova
S. V. Litvinova
OKO. V. Karapetian
O. V. Karapetian

30 April 2020 in Inflammation Research
Verified
Journal Article
Open access
PDF file
VOVolodymyr V. Oberemok
Volodymyr V. Oberemok
KLKateryna V. Laikova
Kateryna V. Laikova
KYKseniya A. Yurchenko
Kseniya A. Yurchenko
IFIrina I. Fomochkina
Irina I. Fomochkina
Anatolii V KubyshkinAnatolii V Kubyshkin
Anatolii V Kubyshkin
At the population level, the virus-host relationship is not set up to end with the complete elimination of either or both. Pathogen-resistant individuals will always remain in the host population. In turn, the virus can never completely eliminate the host population, because evolutionarily such an event is a dead end for the virus as an obligate intracellular parasite. A certain existential balance exists in the virus-host relationship. Against this backdrop, viral epidemics and pandemics only become manifest and egregious to human beings when tens and hundreds of thousands of people die and the question emerges what caused the high mortality peaks on the death chart. The answer seems clear; the emerging strain of the virus is new to the host population, and new mutations of the virus and natural selection will lead to a survival of only genetically resistant individuals in a host population. The dangers inherent to a novel virus are due to new features generally inthe molecular structure of proteins, which enable the virus to infect the cells of the host organism more intensively, dramatically challenging host immunity, and thus be transmitted more readily in the host population. In this article, we will concentrate on the facts currently available about severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which has caused COVID-19 (coronavirus disease 2019) pandemic and try to predict its development and consequences based on the virus-host relationship. In fact, only two scenarios will occur simultaneously in the very near future: people who are genetically resistant to the virus will get sick, recover, and develop immunity, while people who are sensitive to the virus will need drugs and vaccines, which will have to be researched and developed if they are to recover. If the pandemic does not stop, in a few decades it is anticipated that SARS-CoV-2 will become as safe as the four non-severe acute respiratory syndrome human coronaviruses (HCoV-NL63, HCoV-HKU1, HCoV-OC43, and HCoV-229E) currently circulating but causing low mortality in the human population.

Verified
Journal Article
Open access
PDF file
Vol V. OberemokVol V. Oberemok
Vol V. Oberemok
KLKateryna Laikova
Kateryna Laikova
AZAleksei S. Zaitsev
Aleksei S. Zaitsev
MSMaksym Shumskykh
Maksym Shumskykh
IKIgor N. Kasich
Igor N. Kasich
Oleksii SkorokhodOleksii Skorokhod
Oleksii Skorokhod
Baculovirus IAP (inhibitor-of-apoptosis) genes originated by capture of host genes. Unmodified short antisense DNA oligonucleotides (oligoDNAs) from baculovirus IAP genes can down-regulate specific gene expression profiles in both baculovirus-free and baculovirus-infected insects. In this study, gypsy moth (Lymantria dispar) larvae infected with multiple nucleopolyhedrovirus (LdMNPV), and LdMNPV-free larvae, were treated with oligoDNA antisense to the RING (really interesting new gene) domain of the LdMNPV IAP-3 gene. The results with respect to insect mortality, biomass accumulation, histological studies, RT-PCR, and analysis of DNA apoptotic fragmentation suggest that oligoRING induced increased apoptotic processes in both LdMNPV-free and LdMNPV-infected insect cells, but were more pronounced in the latter. These data open up possibilities for promising new routes of insect pest control using antisense phosphodiester DNA oligonucleotides.

12 July 2020 in Inflammation Research
Verified
Journal Article
Closed access
PDF file
VOV. V. Oberemok
V. V. Oberemok
KLK. V. Laikova
K. V. Laikova
KYKseniya A. Yurchenko
Kseniya A. Yurchenko
NMN. A. Marochkin
N. A. Marochkin
IFI. I. Fomochkina
I. I. Fomochkina
Anatolii V KubyshkinAnatolii V Kubyshkin
Anatolii V Kubyshkin